Trial Profile
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms HIMALAYA
- Sponsors AstraZeneca
- 14 Nov 2023 Results (Data-cut off was 23 January 2023 )of updated 4-year OS analysis , presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 29 Jun 2023 Results presented AstraZeneca in the Media Release.
- 29 Jun 2023 Results presented AstraZeneca in the Media Release.